Effects of pioglitazone on plasma adiponectin in patients with type 2 diabetes mellitus: a Meta-analysis

doi:10.19803/j.1672-8629.2022.09.17

Abstract

Abstract: Objective To investigate the impact of pioglitazone on plasma adiponectin levels in patients with type 2 diabetes mellitus through meta-analysis. Methods Wanfang, CNKI, PubMed, the Cochrane Library and Embase were systematically searched for randomized controlled trials of pioglitazone in treatment of type 2 diabetes modulating adiponectin from the establishment to April 30, 2021. Literature selection and data extraction were conducted according to the PRISMA criteria. Quality assessment was conducted according to the Cochrane criteria. Data analysis was done with Revman 5.3 and Stata 14.0 software. Results Ten randomized controlled clinical trials were included. The analysis results demonstrated that pioglitazone treatment significantly increased plasma adiponectin levels by 8.65 μg·mL^-1 (95% CI, 7.18~10.12 μg·mL^-1) compared with placebo. Pioglitazone treatment showed a stronger effect on increasing adiponectin concentrations by 4.92 μg·mL^-1 (95% CI, 3.27~6.58 μg·mL^-1 ) compared with other oral antidiabetic agents. Conclusion Pioglitazone could increase plasma adiponectin concentrations in patients with type 2 diabetes mellitus compared to placebo or other oral antidiabetic agents.

Key words: adiponectin, pioglitazone, type 2 diabetes mellitus, randomized controlled clinical trials, Meta-analysis

CLC Number:

R977.15

MU Sicong, WANG Zhuo, LU Junyang, JI Liwei, LIU Xin. Effects of pioglitazone on plasma adiponectin in patients with type 2 diabetes mellitus: a Meta-analysis[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 1015-1018.

References

[1] FURTADO RHM, BONACA MP, RAZ I, et al.Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction[J]. Circulation, 2019, 139(22): 2516-2527.
[2] KAISANLAHTI A, GLUMOFF T, et al.Browning of white fat: agents and implications for beige adipose tissue to type 2 diabetes[J]. Journal of Physiology and Biochemistry, 2019, 75(1): 1-10.
[3] RODRÍGUEZ A, CATALÁN V, RAMÍREZ B, et al. Impact of adipokines and myokines on fat browning[J]. Journal of Physiology and Biochemistry, 2020, 76(2): 227-240.
[4] CUI M, GAO Y, ZHAO Y, et al.Association between adiponectin gene polymorphism and environmental risk factors of type 2 diabetes mellitus among the Chinese population in hohhot[J]. BioMed research international, 2020(6): 6383906.
[5] LI S, SHIN HJ, DING EL, et al.Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis[J]. JAMA, 2009, 302(2): 179-188.
[6] YANAI H, YOSHIDA H.Beneficial effects of adiponectin on glucose and lipid metabolism and atherosclerotic progression: mechanisms and perspectives[J]. International Journal of Molecular Sciences, 2019, 20(5): 1190
[7] DEFRONZO RA, INZUCCHI S, ABDUL-GHANI M, et al.Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes[J]. Diabetes & Vascular Disease Research, 2019, 16(2): 133-143.
[8] Cochrane. Cochrane Handbook for Systematic Reviews of Interventions[EB/OL].[2022-08-01]. https://training.cochrane.org/handbook.
[9] GASTALDELLI A, MIYAZAKI Y, MAHANKALI A, et al.The effect of pioglitazone on the liver: role of adiponectin[J]. Diabetes Care, 2006, 29(10): 2275-2281.
[10] HANEFELD M, PFUTZNER A, FORST T, et al.Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study[J]. Cardiovascular Diabetology, 2011, 10: 65.
[11] KAKU K.Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial[J]. Current Medical Research and Opinion, 2009, 25(5): 1111-1119.
[12] ERDEM G, DOGRU T, TASCI I, et al.The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus[J]. Diabetes Research and Clinical Practice, 2008, 82(2): 214-218.
[13] ESPOSITO K, MAIORINO MI, PALO CI, et al.Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes--a randomized controlled trial[J]. Diabetes, Obesity & Metabolism, 2011, 13(5): 439-445.
[14] NISHIO K, SAKURAI M, KUSUYAMA T, et al.A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes[J]. Diabetes Care, 2006, 29(1): 101-106.
[15] OZ O, TUNCEL E, ERYILMAZ S, et al.Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones[J]. Endocrine, 2008, 33(1): 101-105.
[16] PFUTZNER A, SCHONDORF T, TSCHOPE D, et al.PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia[J]. Diabetes Technology & Therapeutics, 2011, 13(6): 637-643.
[17] SHARMA PK, BHANSALI A, SIALY R, et al.Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus[J]. Clinical Endocrinology, 2006, 65(6): 722-728.
[18] HE XL, LIU J, ZHANG HX.et al.Comparison of therapeutic effects of pioglitazone and acarbose on elderly patients with type 2 diabetes mellitus and hypertension[J]. Chinese Journal of Multiple Organ Diseases in the Elderly(中华老年多器官疾病杂志), 2014, 13(12): 907-912.
[19] KADOWAKI T, YAMAUCHI T, KUBOTA N, et al.Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome[J]. The Journal of Clinical Investigation, 2006, 116(7): 1784-1792.
[20] YU Y, DU H, WEI S, et al.Adipocyte-derived exosomal MiR-27a induces insulin resistance in skeletal muscle through repression of PPARγ[J]. Theranostics, 2018, 8(8): 2171-2188.
[21] ACHARI AE, JAIN SK.Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction[J]. International Journal of Molecular Sciences, 2017, 18(6): 1321.
[22] ÖZAY Y, OZEK D, YILDIRIM F, et al.The effect of diabetes on vitreous levels of adiponectin and inflammatory cytokines in experimental rat model[J]. Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University, 2020, 29(4): 449-452.
[23] FANG H, JUDD RL.Adiponectin regulation and function[J]. Comprehensive Physiology, 2018, 8(3): 1031-1063.
[24] LEBOVITZ HE.Thiazolidinediones: the forgotten diabetes medications[J]. Current Diabetes Reports, 2019, 19(12): 151.
[25] MARECHAL L, LAVIOLETTE M, RODRIGUE-WAY A, et al.The CD36-PPARγ pathway in metabolic disorders[J]. International Journal of Molecular Sciences, 2018, 19(5) : 1529.
[26] ASTAPOVA O, LEFF T.Adiponectin and PPARγ: cooperative and interdependent actions of two key regulators of metabolism[J]. Vitamins and Hormones, 2012, 90: 143-162.
[27] PEREIRA RI, LEITNER JW, ERICKSON C et al. Pioglitazone acutely stimulates adiponectin secretion from mouse and human adipocytes via activation of the phosphatidylinositol 3’-kinase[J]. Life Sciences, 2008, 83(19-20): 638-643.